WuXi AppTec Recognized for Its Continued Commitment to Environmental, Social, and Governance Excellence
WuXi Biologics a leading global Contract Research, Development, and Manufacturing Organization (CRDMO), has proudly announced its inclusion in the 2024 Dow Jones Sustainability Indices (DJSI) for the second consecutive year. This achievement underscores the company’s unwavering commitment to sustainability and its notable strides in promoting responsible and innovative practices across its operations.
The Dow Jones Sustainability Indices are globally recognized benchmarks that highlight companies excelling in sustainable business practices. Established in 1999, the DJSI was the first global sustainability benchmark, designed to cater to investors who value long-term shareholder returns while aligning their portfolios with sustainability principles. Among these indices, the DJSI World includes the top 10% of the largest 2,500 companies in the S&P Global Broad Market Index based on their environmental, social, and governance (ESG) performance.
Dr. Chris Chen, CEO of WuXi Biologics and Chairman of its ESG Committee, shared his pride in this accomplishment, stating, “We are honored to be included in the DJSI list for the second consecutive year. This recognition reflects our continuous commitment to enhancing sustainability capabilities. As a global leader in Green CRDMO, we strive to deliver ESG excellence while empowering our global partners with end-to-end solutions driven by innovation. Moving forward, we will keep pushing industry boundaries and collaborate with stakeholders to promote responsible practices throughout the entire value chain.”
Advancing Sustainability as a Core Value
WuXi Biologics’ commitment to sustainability is evident in its comprehensive approach to embedding ESG principles throughout its business. The company has made significant investments in green technologies, efficient manufacturing processes, and initiatives aimed at reducing environmental impacts. This holistic approach not only enhances operational efficiency but also reinforces the company’s role as a sustainable partner for its clients.
As part of its sustainability efforts, WuXi Biologics has focused on developing innovative solutions that meet the highest environmental standards. Its advanced green biologics technologies have set benchmarks in the industry, aligning with global efforts to transition to more sustainable pharmaceutical development and manufacturing practices. These initiatives contribute to reducing carbon footprints and resource consumption while delivering high-quality, life-saving biologics to patients worldwide.
WuXi Biologics’ commitment to sustainability is evident in its comprehensive approach to embedding ESG principles throughout its business. The company has made significant investments in green technologies, efficient manufacturing processes, and initiatives aimed at reducing environmental impacts. This holistic approach not only enhances operational efficiency but also reinforces the company’s role as a sustainable partner for its clients.
As part of its sustainability efforts, WuXi Biologics has focused on developing innovative solutions that meet the highest environmental standards. Its advanced green biologics technologies have set benchmarks in the industry, aligning with global efforts to transition to more sustainable pharmaceutical development and manufacturing practices. These initiatives contribute to reducing carbon footprints and resource consumption while delivering high-quality, life-saving biologics to patients worldwide.
WuXi Biologics’ sustainability strategy reflects a forward-thinking vision that integrates environmental, social, and governance (ESG) principles into its long-term goals. By embracing state-of-the-art technologies, the company enhances energy efficiency, minimizes waste, and adopts advanced water stewardship practices. These efforts are instrumental in reducing environmental impact while ensuring operational excellence.
Through its “Green CRDMO” strategy, WuXi Biologics actively collaborates with global partners to promote responsible practices across the value chain. By offering end-to-end solutions driven by innovation, the company empowers its partners to meet sustainability goals, demonstrating that ESG excellence is both attainable and essential in the biopharmaceutical industry.
Recognitions and Achievements
Over the years, WuXi Biologics has been acknowledged for its exceptional contributions to sustainable development. Among its accolades:
- UNGC 20 Case Examples: WuXi Biologics was included in the United Nations Global Compact (UNGC) 20 Case Examples of Sustainable Development for its pioneering green biologics solutions. This recognition highlights the company’s leadership in advancing sustainability in the pharmaceutical industry.
- MSCI ESG Ratings: The company earned an AAA rating from MSCI ESG Ratings for two consecutive years, underscoring its robust ESG performance and risk management capabilities.
- EcoVadis Platinum Medal: WuXi Biologics was awarded the prestigious Platinum Medal by EcoVadis, placing it among the top-performing companies in terms of sustainability practices.
- Sustainalytics Rankings: The company was recognized as an Industry and Regional Top-Rated Company by Sustainalytics, further demonstrating its commitment to ESG excellence.
- CDP Ratings: WuXi Biologics was named to the CDP Water Security “A List” and received an “A-” score for Climate Change, reflecting its proactive measures to address water and climate-related challenges.
- FTSE4Good Index Series: Inclusion in the FTSE4Good Index Series affirmed the company’s adherence to globally recognized ESG standards.
- Hang Seng ESG 50 Index: WuXi Biologics was listed as a constituent of the Hang Seng ESG 50 Index, further solidifying its position as a sustainability leader in the industry.
A Vision for the Future
WuXi Biologics’ approach to ESG goes beyond compliance and recognition. The company has established a forward-looking vision that integrates sustainability into its long-term strategy. By leveraging innovation, collaboration, and transparency, WuXi Biologics aims to create value for its stakeholders while addressing global challenges such as climate change, resource scarcity, and equitable access to healthcare.
Central to this vision is the company’s “Green CRDMO” strategy, which emphasizes:
- Energy Efficiency: Implementing state-of-the-art technologies to reduce energy consumption across facilities.
- Waste Reduction: Minimizing waste generation through sustainable manufacturing processes and recycling initiatives.
- Water Stewardship: Enhancing water management practices to preserve this vital resource.
- Carbon Neutrality: Setting ambitious targets to achieve carbon neutrality and contribute to global climate goals.
Empowering Global Partnerships
WuXi Biologics’ dedication to sustainability extends to its partnerships with global clients. By providing end-to-end solutions that integrate ESG principles, the company empowers its partners to achieve their sustainability goals. This collaborative approach ensures that the entire value chain benefits from responsible practices, ultimately enhancing the overall impact on society and the environment.
The company’s innovative solutions have been instrumental in driving progress across various sectors. From developing eco-friendly manufacturing platforms to enabling access to affordable biologics, WuXi Biologics continues to play a pivotal role in shaping a more sustainable future for the pharmaceutical industry.
WuXi Biologics’ dedication to sustainability extends to its partnerships with global clients. By providing end-to-end solutions that integrate ESG principles, the company empowers its partners to achieve their sustainability goals. This collaborative approach ensures that the entire value chain benefits from responsible practices, ultimately enhancing the overall impact on society and the environment.
The company’s innovative solutions have been instrumental in driving progress across various sectors. From developing eco-friendly manufacturing platforms to enabling access to affordable biologics, WuXi Biologics continues to play a pivotal role in shaping a more sustainable future for the pharmaceutical industry.
Through its “Green CRDMO” strategy, WuXi Biologics focuses on reducing environmental impacts while maintaining high-quality standards. Key initiatives include energy efficiency measures, waste reduction programs, and advanced water management practices. These efforts not only optimize resources but also contribute to global goals such as carbon neutrality and climate resilience.
WuXi Biologics has received numerous recognitions for its ESG contributions, including an AAA rating from MSCI ESG Ratings and a Platinum Medal from EcoVadis. These accolades underscore the company’s leadership in sustainable development and its role in driving positive change across the industry.
By fostering partnerships rooted in innovation and responsibility, WuXi Biologics demonstrates how collaborative efforts can transform the pharmaceutical landscape. As the company continues to advance its sustainability mission, it remains a beacon of progress and a catalyst for a healthier, more sustainable world.
Commitment to Continuous Improvement
While WuXi Biologics’ achievements in sustainability are commendable, the company recognizes the need for continuous improvement. It remains dedicated to advancing its ESG capabilities and exploring new opportunities to make a positive impact. By fostering a culture of innovation and responsibility, WuXi Biologics aims to stay at the forefront of sustainable development in the biopharmaceutical sector.
